RxDoctor Payments Data

Daniel Koenig

Optometrist · Ames, IANPI 1235129917

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,905 of the $10,856 with a category attached, or 63.6%. Alcon accounts for 86.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $5,293 and has fallen 83.0% since, to $900 in 2025. Among optometrist clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,856in general payments, 2019–2025

Across 211 payments — averaging $51.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$9K
  • Coopervision Inc.$434
  • Bausch & Lomb Americas Inc.$391
  • Tarsus Pharmaceuticals, Inc.$262
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$153
  • Johnson & Johnson Vision Care, Inc.$150
  • plus $113 from 4 others

What the payments were for

  • Speaking & faculty fees$6,90564%
  • Food & beverage$3,93136%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,856 in reported general payments places this provider in the 95th percentile of 559 optometrist providers in Iowa.

See all optometrist providers in Iowa

Medicare billing

Part B allowed, 2024
$106,808
Medicare patients
528
Services billed
1,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol12$5,118
Latanoprost178$1,245
Prednisolone Acetate17$564
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$294
Timolol Maleate23$226
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha19$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$17$5,11812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 optometrist providers in Iowa.

Other optometrist in Ames

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →